000			03552nam a22003738i 4500
001			CR9780511618871
003			UkCbUP
005			20200124160313.0
006			m|||||o||d||||||||
007			cr||||||||||||
008			090915s2007||||enk o ||1 0|eng|d
020			_a9780511618871 (ebook)
020			_z9780521874908 (hardback)
020			_z9781107460010 (paperback)
040			_aUkCbUP _beng _erda _cUkCbUP
050	0	0	_aRA401.A1 _bP43 2007
082	0	0	_a338.4/76151 _222
245	0	0	_aPharmaceutical innovation : _bincentives, competition, and cost-benefit analysis in international perspective / _cedited by Frank A. Sloan, Chee-Ruey Hsieh.
264		1	_aCambridge : _bCambridge University Press, _c2007.
300			_a1 online resource (xiv, 331 pages) : _bdigital, PDF file(s).
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
500			_aTitle from publisher's bibliographic system (viewed on 05 Oct 2015).
505	0		_aIntroduction / Frank A. Sloan and Chee-Ruey Hsieh -- The pharmaceutical sector in health care / Uwe E. Reinhardt -- The economics of research and development in the pharmaceutical industry / William S. Comanor -- Drugs for neglected diseases: new incentives for innovation / Aidan Hollis -- When patents fail: finding new drugs for the developing world / Stephen M. Maurer -- Implementing a public subsidy for vaccines / Frank A. Sloan and Charles E. Eesley -- Ensuring the future supply of vaccines: is a national vaccine authority the answer? / Frank R. Lichtenberg -- Competition between generic and branded drugs / Henry Grabowski -- The United States' experience with direct-to-consumer advertising of prescription drugs: what have we learned? / Ernst R. Berndt -- Measures of costs and benefits for drugs in cost-effectiveness analysis / Mark V. Pauly -- Using economic evaluation in reimbursement decisions for health technologies: lessons from international experience / Michael Drummond -- Pharmaceutical spending and health outcomes / Pierre-Yves Cremieux [and others] -- Pharmaceutical innovation and health outcomes: empirical evidence from Taiwan / Chee-Ruey Hsieh [and others] -- Conclusions and policy implications / Frank A. Sloan and Chee-Ruey Hsieh.
520			_aThe pharmaceutical industry worldwide is a rapidly burgeoning industry contributing to growth of gross domestic product and employment. Technological change in this field has been very rapid, with many new products being introduced. For this reason in part, health care budgets throughout the world have increased dramatically, eliciting growing pressures for cost containment. This book explores four important issues in pharmaceutical innovations: (1) the industry structure of pharmaceutical innovation; (2) incentives for correcting market failures in allocating resources for research and development; (3) competition and marketing; and (4) public evaluation of the benefits and costs of innovation. The lessons are applicable to countries all over the world, at all levels of economic development. By discussing existing evidence this book proposes incentive arrangements to accomplish social objectives.
650		0	_aPharmaceutical policy.
650		0	_aPharmaceutical industry.
650		0	_aDrug development _xTechnological innovations _xEconomic aspects.
700	1		_aSloan, Frank A., _eeditor.
700	1		_aHsieh, Chee-Ruey, _eeditor.
776	0	8	_iPrint version: _z9780521874908
856	4	0	_uhttps://doi.org/10.1017/CBO9780511618871
999			_c521242 _d521240